Premium
O4‐09‐03: Ttp488: From futile to fast track
Author(s) -
Sabbagh Marwan N.,
Burstein Aaron,
Grimes Imogene,
Valcarce Carmen,
Rose Eric,
Doody Rachelle S.,
Sano Mary,
Schneider Lon S.,
Galasko Douglas
Publication year - 2015
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2015.07.395
Subject(s) - post hoc analysis , placebo , clinical endpoint , analysis of covariance , repeated measures design , descriptive statistics , medicine , post hoc , gee , subgroup analysis , psychology , randomized controlled trial , statistics , generalized estimating equation , meta analysis , mathematics , alternative medicine , pathology
general health was installed in the homes of 108 older adults from the ORCATECH Life Laboratory who lived alone from July 2011 – March 2014 (age 81.5 6 6.6 years, 82% female). MCI severity was assessed yearly by the Clinical Dementia Rating Sum of Box Score (CDR-SB). Everyday activities – e.g., computer use and sleep hygiene – were assessed using validated algorithms. Longitudinal regression models examined the relationship between both home monitored measures and MCI, and several conventional measures of cognitive and physical function with MCI. Results:The mean CDR-SB was 0.1 at baseline and increased to 0.25 a mean of 25.7 months later. 65,949,179 data points were captured at a 1-minute interval over the monitoring period. The clinical assessment explained 42% (p<0.0001) of the variance in CDR-SB scores over the monitoring period. Home monitoring data without other clinical data explained 24% (p<0.0001) of this variance while a combined model explained 56% (p<0.0001) of this variance. Conclusions: The results suggest that home monitoring metrics capture important aspects of cognitive function not captured by traditional clinical assessment. Additionally, the continuous measurement from the home platform allows more frequent assessment of function than is possible clinically, allowing detection of key changes when they occur. Taken together, these results suggest that home monitoring may be a simple way to address some of the assessment shortcomings present in current AD clinical trials.